|Series A, 8/12 ||$7M|
Retia Medical develops monitors for high-risk patients. Retia’s first product monitors cardiac output, a critical health metric that indicates the flow rate of blood pumped by the heart. The initial target market for this technology is the ICU and perating rooms. It is potentially extendable for use in emergency rooms or at home. Based in East Lansing, MI, Retia’s technology was exclusively licensed from MSU and validated through extensive tests in animals and humans. With the support of the Pritzker/Vlock family office and a strong advisory board composed of industry and clinical experts, Retia will seek FDA approval and launch this product, which will help revolutionize the care of our most at-risk patients.